A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT04802759
This study is recruiting at 9 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Hoffmann-La Roche
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 5
- City of Hope · Duarte, CA
- City of Hope - Orange County Lennar Foundation Cancer Center · Irvine, CA
- University of California, San Francisco (UCSF) · San Francisco, CA
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Santa Monica, CA
- Stanford Cancer Institute (SCI) · Stanford, CA
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
North Carolina · 1
- Levine Cancer Institute · Charlotte, NC
Pennsylvania · 1
- Thomas Jefferson University Hospital · Philadelphia, PA
Tennessee · 1
- West Cancer Center · Germantown, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.